|
[1]Seeff LB.Natural history of hepatitis C[J].Hepatology,1997,26(3 Suppl 1):S21-28.
|
|
[2]Shepard CW,Finelli L,Alter MJ.Global epidemiology of hepatitis C virus infection[J].Lancet Infect Dis,2005,5(9):558-567.
|
|
[3]Lauer GM,Walker BD.Hepatitis C virus infection[J].N Engl J Med,2001,345(1):41-52.
|
|
[4]Perz JF,Armstrong GL,Farrington LA,et al.The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide[J].J Hepatol,2006,45(4):529-538.
|
|
[5]Hoofnagle JH,Mullen KD,Jones DB,et al.Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon.A preliminary report[J].N Engl J Med,1986,315(25):1575-1578.
|
|
[6]Global surveillance and control of hepatitis C.Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board,Antwerp,Belgium[J].JViral Hepat,1999.6(1):35-47.
|
|
[7]Lindenbach BD,Rice CM.Unravelling hepatitis C virus replication from genome to function[J].Nature,2005,436(7053):933-938.
|
|
[8]Kwong AD,McNair L,Jacobson I,et al.Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors[J].Curr Opin Pharmacol,2008,8(5):522-531.
|
|
[9]Reesink HW,Zeuzem S,Weegink CJ,et al.Rapid decline of viral RNA in hepatitis C patients treated with VX-950:a phase Ib,placebo-controlled,randomized study[J].Gastroenterology,2006,131(4):997-1002.
|
|
[10]Zeuzem S.Telaprevir,peginterferon alfa-2a,and ribavirin for 28 days in chronic hepatitis C patients[J].J Hepatol,2008,49(2):157-159.
|
|
[11]de Bruijne J,Weegink CJ,Jansen PL,et al.New developments in the antiviral treatment of hepatitis C[J].Vox Sang,2009,97(1):1-12.
|
|
[12]Kwo P.HCV SPRINT-1:boceprevir plus peginterferon-alfa-2b/ribavirin for treatment of genotype 1 chronic hepatitis C in previously untreated patients[R].The 59th Annual Meeting of the American Association for the Study of Liver Diseases 2008.
|
|
[13]Schiff E,Poordad F,Jacobson I,et al.Boceprevir(B)combination therapy in null responders(NR):Response dependent on interferon responsiveness[J].J Hepatology,2008,48(2):S46.
|
|
[14]Reddy R.Antiviral activity,pharmacokinetics,safety,and tolerability of R7128,a novel nucleoside HCV RNA polymerase inhibitor,following multiple,ascending oral doses inpatients with HCV genotype 1 infection who have failed prior interferon therapy[R].The 57th Annual Meeting of the American Association for the Study of Liver Diseases,2006.
|
|
[15]Nicolas O.Genotypic analysis of HCV NS5B variants selected from patients treated with VCH-759[R].The 41st Annual Meeting of the European Association for the Study of the Liver,2008.
|
|
[16]Nettles R.BMS-790052 is a first-in-class potent hepatitis C virus(HCV)NS5A inhibitor for patients with chronic HCV infection:Results from a proof-of-concept study[R].The 59th Annual Meeting of the American Association for the Study of Liver Diseases,2008.
|
DownLoad: